DBV Technologies (NASDAQ:DBVT) Rating Increased
Societe Generale increased Dbv Technologies (NASDAQ:DBVT)’s stock to Buy rating from Hold. This rating change was issued to investors and clients in a research report today.
In spite of this rating upgrade NASDAQ:DBVT is now trading 0.00% lower at $35.57 as of 2:03 AM New York time. DBV Technologies shares have [From2] 0% over the past 200 days, while the S&P 500 Index has added 13.63% for the same time.
According to data compiled by Thomson Reuters, DBV Technologies (NASDAQ:DBVT)’s stock is covered by 7 equity analysts across the Street, with 0 analysts giving it a Sell rating, 7 a Buy rating, while 0 consider it a Hold. The 12-month consensus target price for the stock is $53.5, which reflects an upside potential of 50.41% over the current price.
DBV Technologies (NASDAQ:DBVT) Profile
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock.
DBV Technologies (NASDAQ:DBVT) closed at $35.57 yesterday. A total of 1,300 shares of the company’s stock traded hands. This is down from average of 81,405 shares. DBV Technologies has a 52 week low of $27.02 and a 52 week high of $37.98. The company has a market cap of $1.75B and a P/E ratio of 0.
Get the latest DBV Technologies (NASDAQ:DBVT) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
The post DBV Technologies (NASDAQ:DBVT) was Improved at Societe Generale from a Hold Rating to Buy One appeared first on Octafinance.